Mumbai, February 09, 2026: Informa Markets in India has undertaken a ₹50 lakh corporate social responsibility (CSR) initiative to strengthen public healthcare diagnostics in Mumbai by donating critical diagnostic equipment to a government hospital. The intervention is expected to generate annual healthcare cost savings exceeding ₹100 crore for underserved communities by sharply reducing the cost of essential diagnostic tests.
As part of the initiative, Informa Markets in India donated a chemiluminescence immunoassay (CLIA) analyser to Dr. R. N. Cooper Municipal General Hospital, also known as Hinduhridaysamrat Balasaheb Thackeray (HBT) Medical College & Hospital. The tertiary care facility serves large populations across Mumbai’s western suburbs and operates under the Brihanmumbai Municipal Corporation.
The CSR programme was implemented in partnership with Child Help Foundation, a pan-India non-profit organisation working across health, education, nutrition and community-based interventions.
The CLIA analyser is an automated, high-sensitivity diagnostic system used for detecting hormones, tumour markers, infectious disease indicators and reproductive health markers. Designed for high-volume settings, the system offers rapid turnaround times and high accuracy, making it well suited for public hospitals with heavy patient loads.
In private laboratories, CLIA-based diagnostic tests typically cost between ₹1,200 and ₹2,500 per test. With the new equipment installed, the same tests can now be offered at Dr. R. N. Cooper Hospital at approximately ₹150–₹200 per test, resulting in an estimated cost reduction of 85–90% for patients. Based on current patient volumes, the initiative is projected to deliver ₹120–₹240 crore in annual savings for communities that depend on public healthcare services.
The hospital is a major referral and teaching institution offering multi-specialty services, including general medicine, surgery, paediatrics, obstetrics and gynaecology, orthopaedics and pulmonary medicine, supported by facilities such as a neonatal intensive care unit, blood bank and specialised diagnostic services. The addition of the CLIA analyser is expected to reduce diagnostic wait times, support quicker clinical decision-making and enable earlier treatment, particularly for patients who may delay or avoid testing due to cost constraints.
Mr. Yogesh Mudras, Managing Director, Informa Markets in India, said, “We believe CSR is most meaningful when it strengthens systems rather than addresses symptoms. By investing in diagnostic infrastructure within a public hospital, we are helping reduce the cost barrier at the very first point of care—testing—so that timely treatment becomes possible for thousands of patients every year. This is the kind of long-term, multiplier-effect impact we aim to create.”
He added, “As an organisation, Informa Markets in India has always tried to create an impact where the seeds sown today create a huge impact on our tomorrows. Often related to the sectors we serve, our endeavours are invariably linked to children’s health, education, and their capacity to flourish with encouragement and the right environment.”
The initiative highlights how targeted infrastructure investments within public health systems can deliver sustained, measurable benefits by improving access, affordability and quality of care for underserved populations.
x
.jpg)
.jpg)
